Table 4. Serum biomarkers of patients with EGPA based on use of immunosuppressive agents at time of study visit.

Serum parameters	No immunosuppr. use (n = 32)	Immunosuppr. use (n = 73)	MWU	LR
Eotaxin-3 [pg/ml]	1.6 (0–555.5)	0 (0–92.2)	0.015	0.06
TARC/CCL17 [pg/ml]	386.3 (97.1–2684.6)	288.3 (98.8–4549.4)	0.28	0.47
IgG4 [mg/dL]	19.5 (8–479)	62.4 (7–337)	0.15	0.74
IgG4/IgG ratio*100	2.9 (1–32.0)	7.1 (1–28.0)	0.079	0.58
ESR [mm/1st hour]	4 (1–20)	8 (1–40)	0.031	0.07
CRP [mg/L]	3.5 (0.1–21.0)	2.0 (0.1–32.9)	0.23	0.42
Eosinophils (%)	5.5 (0.7–33.6)	4.0 (0.1–50.0)	0.46	0.41

Data are shown as median (range in parenthesis); EGPA: eosinophilic granulomatosis with polyangiitis (Churg-Strauss); immunosuppr., immunosuppressive agents (9 patients were on methotrexate, 7 on azathioprine and 1 on mycophenolate mofetil); LR, Logistic regression analysis as described in Materials and Methods; MWU, Mann Whitney U test; n, number of visits